Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + interferon alfa-2b
- Development stage
- Phase 2
- Lead developer
- Bristol Myers Squibb
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
This neoadjuvant combination immunotherapy regimen consists of ipilimumab, a monoclonal antibody targeting the CTLA-4 checkpoint, and high-dose interferon alpha-2b (HDI), an immunomodulatory cytokine. Evaluated in a randomized Phase 1 study (NCT01608594) led by Dr. Diwakar Davar at the University of Pittsburgh, the treatment is intended for patients with locally or regionally advanced or recurrent melanoma. Ipilimumab (Yervoy) enhances T-cell activation by blocking inhibitory signals from CTLA-4, while interferon alpha-2b (Intron A) exerts pleiotropic effects including enhancement of MHC expression and activation of natural killer cells. The regimen is administered prior to definitive surgery to achieve pathologic complete responses and improve long-term outcomes.
- Other names
- ipilimumab + HDIneoadjuvant ipilimumab and high-dose interferon alpha-2bipilimumab + high-dose interferon alpha-2b
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on ipilimumab + interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + interferon alfa-2b.